Diplomat Pharmacy (DPLO) Stock Price Up 10.7% After Analyst Upgrade
Diplomat Pharmacy Inc (NYSE:DPLO)’s share price rose 10.7% during mid-day trading on Monday after Needham & Company LLC raised their price target on the stock from $24.00 to $26.00. Needham & Company LLC currently has a buy rating on the stock. Diplomat Pharmacy traded as high as $23.08 and last traded at $22.99. Approximately 2,577,700 shares were traded during trading, an increase of 145% from the average daily volume of 1,050,375 shares. The stock had previously closed at $20.77.
Several other equities analysts also recently issued reports on the stock. Robert W. Baird downgraded shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub downgraded shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Deutsche Bank started coverage on shares of Diplomat Pharmacy in a report on Monday, December 4th. They set a “buy” rating and a $22.00 price objective on the stock. Mizuho increased their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, November 7th. Finally, Leerink Swann upgraded shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research report on Monday, December 11th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $20.94.
In other Diplomat Pharmacy news, CFO Atul Kavthekar bought 2,000 shares of Diplomat Pharmacy stock in a transaction dated Monday, November 20th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $30,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey G. Park bought 3,000 shares of Diplomat Pharmacy stock in a transaction dated Monday, November 20th. The stock was acquired at an average price of $15.46 per share, with a total value of $46,380.00. Following the completion of the transaction, the director now directly owns 7,640 shares of the company’s stock, valued at $118,114.40. The disclosure for this purchase can be found here. Insiders bought 15,000 shares of company stock valued at $228,780 over the last quarter. Company insiders own 30.20% of the company’s stock.
The firm has a market cap of $1,600.00, a PE ratio of 197.25, a PEG ratio of 3.62 and a beta of 0.62. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the business earned $0.21 earnings per share. Diplomat Pharmacy’s revenue was down 4.8% compared to the same quarter last year. sell-side analysts predict that Diplomat Pharmacy Inc will post 0.85 earnings per share for the current fiscal year.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.